Patient Blood Management: Where Perfusion Cuts Cost and Complications at Once

Most cost-reduction efforts force a trade-off between the ledger and the patient. Patient blood management in cardiac surgery is the rare initiative where the two move in the same direction — and cardiovascular perfusion sits at the center of it.

Why blood is a bigger number than it looks

The acquisition price of a unit of red cells is only the visible tip. The fully activity-based cost — type and screen, storage, administration, monitoring, and the downstream management of transfusion-related complications — is several times higher. Cardiac surgery consumes a disproportionate share of the hospital's blood supply, which makes it one of the highest-yield places to intervene.

Transfusion is not a neutral event

A substantial body of cardiac surgery literature associates allogeneic transfusion with increased risk of infection, acute kidney injury, prolonged ventilation, longer length of stay, and higher mortality. Under bundled payments and readmission penalties, every one of those complications is also a financial event. Reducing unnecessary transfusion lowers cost twice: once on the product, and again on the complications it helps avoid.

The levers perfusion actually controls

These are not administrative policies imposed from above — they are perfusion practice decisions made case by case. Which is exactly why a blood management program that ignores the perfusion team rarely works, and one built around it usually does.

What to measure

When these metrics are tracked and benchmarked, variation appears quickly — and variation is the opportunity. Closing it protects patients and margin at the same time, which is the kind of initiative that clears both the CMO's desk and the CFO's.